Eris Lifesciences Limited (NSE:ERIS)
1,414.40
-96.00 (-6.36%)
At close: Feb 13, 2026
Eris Lifesciences Revenue
Eris Lifesciences had revenue of 7.90B INR in the quarter ending September 30, 2025, with 6.93% growth. This brings the company's revenue in the last twelve months to 29.86B, up 20.16% year-over-year. In the fiscal year ending March 31, 2025, Eris Lifesciences had annual revenue of 28.79B with 44.59% growth.
Revenue (ttm)
29.86B
Revenue Growth
+20.16%
P/S Ratio
6.39
Revenue / Employee
9.14M
Employees
3,354
Market Cap
195.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | 11.93B | 1.34B | 12.71% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ipca Laboratories | 95.20B |
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Alembic Pharmaceuticals | 72.67B |
| Gland Pharma | 61.13B |
| Ajanta Pharma | 52.02B |
| Strides Pharma Science | 47.26B |
| NATCO Pharma | 45.63B |
Eris Lifesciences News
- 2 days ago - Eris Lifesciences Ltd (NSE:ERIS) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - GuruFocus
- 2 days ago - Q3 2026 Eris Lifesciences Ltd Earnings Call Transcript - GuruFocus
- 2 days ago - Eris Lifesciences Q3 Results: Revenue jumps 10% YoY to Rs 807 crore, net profit up 19% - Business Upturn
- 3 months ago - Eris Lifesciences Ltd (NSE:ERIS) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 3 months ago - Q2 2026 Eris Lifesciences Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Eris Lifesciences Q2 Results: Net profit jumps 31% YoY to Rs 120 crore, revenue up 6.3% - Business Upturn
- 6 months ago - Eris Lifesciences secures ANVISA approval for Ahmedabad sterile injectable facility - Business Upturn
- 6 months ago - Eris Lifesciences secures approval from ANVISA for Ahmedabad facility - Business Upturn